Dr Kimberly A. Brown received her undergraduate degree from the University of Michigan in 1981. She completed her medical degree at Wayne State University in 1985. She completed both her residency in internal medicine as well as her fellowship in gastroenterology at the University of Michigan in 1992, and was named chief medical resident in 1984-1985. She joined the Henry Ford Medical Group in 1995 as medical director of the liver transplant program. In addition, she served as the program director for the GI fellowship program from 2003 to 2008. She is currently the Chief of gastroenterology and hepatology at Henry Ford Hospital in Detroit.
Dr Brown is a fellow of the American Association for the Study of Liver Disease and the American Society of Transplantation. She is a member of the American Gastroenterology Association, the American College of Gastroenterology, and the European Association for the Study of Liver Disease. She served on the Board of Governors of the Henry Ford Medical Group for 9 years, the Henry Ford Hospital and System Network Board for 4 years, and was past co-chair of the Michigan Chapter of the American Liver Foundation. She served as a board member and treasurer for the Board of the American Society of Transplantation and is involved with several committees for both the society and hospital. She is a past member of the UNOS Liver and Intestines Committee and the Executive Board for the Liver and Intestines Community of Practice for the AST.
Dr Brown's major areas of interests are viral hepatitis, liver cancer, liver transplantation, and education. She has trained over 100 GI/liver fellows and has published over 70 peer reviewed articles and reviews in addition to several chapters. She is also a current award winner of the Castle Connelly National Top Doc Award for Clinical Excellence and Henry Ford Medical Group Fred Whitehouse Award for Clinical Excellence.
Conflict of Interest
Dr. Kimberly A. Brown provides advisory services for AbbVie, Bristol-Myers Squibb, Gilead and Merck and has received research grants from AbbVie, Gilead, Duke Research Institute and Novartis.